News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: Yoga = chill. Fact. And ASX health stocks up for second week
Health & Biotech
ASX Health Stocks: Botanix Pharma plunges 25pc after FDA requests this minor change
Health & Biotech
2023 ASX biotech darling Neuren among sector stocks with upcoming catalysts
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as big names ‘trading at very attractive fundamentals’
News
ASX Health Stocks: Living Cells Tech files a patent for cannabis-based dementia drug
News
CLOSING BELL: ASX caps off good week as emerging companies index rises 1.27pc
Health & Biotech
ScoPo’s (actually Wilkie’s) Powerplays: ASX health stocks up as Avita Medical gets US FDA green light
Health & Biotech
ASX Health Stocks: Avita jumps 14pc on FDA approval; Emyria to start trial on landmark MDMA therapy
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech
ASX Health Stocks: Little Green Pharma gets French deal extension; FDA approves Immuron trial
Health & Biotech
ASX Health Stocks: CardieX jumps 16pc after FDA clearance; 3 other ASX biotechs to commence trials
Health & Biotech
ScoPo’s Powerplays: ASX health stocks drop as Neuren surges 60% on US FDA approval
Health & Biotech
ASX Health Stocks: Clarity Pharma shows effectiveness in diagnosing prostate lesions in Phase 1 trial
Health & Biotech
ASX Health Stocks: Emyria surges another 10pc; cannabis play Vitura delivers record profit
Health & Biotech
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
Health & Biotech
ScoPo’s Powerplays: ASX health stocks dancing to a positive tune
Health & Biotech
